Aetna completely out of ACA exchanges for 2018

Making good on promises made by its CEO earlier this year, Aetna confirmed it will not offer policies on the Affordable Care Act (ACA) exchanges in any market for 2018.

The insurer had already announced exits from Virginia and Iowa. Aetna spokesperson T.J. Crawford confirmed via Twitter on May 10 the company wouldn’t be offering plans in Nebraska or Delaware on the on- or off-exchange individual markets, which completes its exits from the exchanges.

A follow-up tweet from Crawford said the company took heavy losses on its 2016 individual market plans, losing $450 million serving 964,000 members. Despite reducing its participation for 2017, its projecting another loss of around $200 million.

The exit is far from a surprise. Aetna CEO Mark Bertolini said in January it had “no intention” of participating in 2018. He later claimed the markets were in a “death spiral,” an assertion disputed by health policy researchers at the Brookings Institution.

The motivation behind Aetna’s reduced participation was questioned in the antitrust ruling blocking its proposed merger with Humana. According to the ruling by U.S. District Court Judge John Bates, Aetna pulled out of markets for 2017 to “improve its position” in the lawsuit, not for business reasons, seeking leverage against the U.S. Department of Justice (DOJ).

“Bertolini believed that DOJ should not block the merger in view of Aetna’s role in advancing the ACA and participating in the exchanges, and Aetna was willing to offer to expand its participation in the exchanges if DOJ did not block the merger, or conversely, was willing to threaten to limit its participation in the exchanges if DOJ did,” Bates wrote.

Aetna’s exit follows Humana’s full departure from the exchanges, which was announced just hours after Bates ruled against their merger.

With the insurer’s departure, Medica is left as the last exchange insurer for Nebraska and Highmark Blue Cross Blue Shield as the final option for Delaware customers. A recent study by the Urban Institute found exchange shoppers on single-insurer exchanges are likely to pay higher premiums. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.